Our prior research demonstrated that ropivacaine has a direct inhibitory effect on the proliferation of lung adenocarcinoma cells, mediated by the angiotensin-converting enzyme 2 (ACE2) receptor [6]. The gene discussed is ACE2; the disease is lung adenocarcinoma.